uniQure N.V.

LSE:0EE0 Stock Report

Market Cap: US$853.0m

uniQure Valuation

Is 0EE0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0EE0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0EE0 ($17.05) is trading below our estimate of fair value ($81.33)

Significantly Below Fair Value: 0EE0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0EE0?

Key metric: As 0EE0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0EE0. This is calculated by dividing 0EE0's market cap by their current revenue.
What is 0EE0's PS Ratio?
PS Ratio29.8x
SalesUS$28.59m
Market CapUS$853.00m

Price to Sales Ratio vs Peers

How does 0EE0's PS Ratio compare to its peers?

The above table shows the PS ratio for 0EE0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12x
OXB Oxford Biomedica
4.6x21.2%UK£446.5m
GNS Genus
1.5x3.7%UK£998.5m
BVXP Bioventix
12.3xn/aUK£167.0m
OPTI OptiBiotix Health
29.7xn/aUK£16.9m
0EE0 uniQure
29.8x39.2%US$853.0m

Price-To-Sales vs Peers: 0EE0 is expensive based on its Price-To-Sales Ratio (29.8x) compared to the peer average (12x).

Price to Sales Ratio vs Industry

How does 0EE0's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.5x3.7%US$1.26b
TRX Tissue Regenix Group
1.7x15.1%US$52.87m
VRCI Verici Dx
2.3x78.8%US$9.92m
DEST Destiny Pharma
3.5x-171.4%US$5.85m
0EE0 29.8xIndustry Avg. 8.1xNo. of Companies6PS01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0EE0 is expensive based on its Price-To-Sales Ratio (29.8x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is 0EE0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0EE0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29.8x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: 0EE0 is expensive based on its Price-To-Sales Ratio (29.8x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0EE0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$17.05
US$30.34
+77.9%
37.4%US$56.82US$19.73n/a10
Dec ’25US$5.97
US$18.65
+212.4%
40.8%US$27.54US$6.77n/a11
Nov ’25US$5.73
US$19.44
+239.3%
38.8%US$28.38US$7.10n/a11
Oct ’25US$4.66
US$19.66
+321.9%
40.8%US$28.79US$7.20n/a10
Sep ’25US$5.88
US$19.77
+236.3%
40.6%US$28.89US$7.22n/a10
Aug ’25US$7.64
US$18.88
+147.2%
39.7%US$28.02US$7.00n/a10
Jul ’25US$4.44
US$18.60
+319.0%
43.6%US$28.31US$6.07n/a10
Jun ’25US$4.86
US$18.44
+279.4%
43.5%US$28.05US$6.01n/a10
May ’25US$4.41
US$20.24
+359.1%
37.6%US$29.55US$7.02n/a11
Apr ’25US$5.29
US$21.90
+313.9%
42.3%US$37.87US$6.98n/a11
Mar ’25US$5.70
US$22.64
+297.1%
39.2%US$37.55US$7.01n/a12
Feb ’25US$5.55
US$30.33
+446.9%
47.7%US$64.09US$9.98n/a12
Jan ’25US$6.74
US$30.83
+357.8%
47.1%US$64.34US$10.02n/a12
Dec ’24US$7.03
US$33.17
+371.9%
40.9%US$64.55US$14.37US$5.9711
Nov ’24US$5.68
US$34.25
+503.0%
34.8%US$53.70US$13.98US$5.7312
Oct ’24US$6.67
US$35.23
+428.1%
32.6%US$53.98US$13.83US$4.6612
Sep ’24US$8.89
US$37.81
+325.3%
31.8%US$55.17US$13.79US$5.8814
Aug ’24US$10.52
US$43.77
+316.1%
38.8%US$90.27US$14.02US$7.6414
Jul ’24US$11.26
US$46.40
+312.0%
36.2%US$89.52US$13.93US$4.4414
Jun ’24US$19.21
US$50.30
+161.9%
28.0%US$89.52US$23.62US$4.8614
May ’24US$19.00
US$55.18
+190.4%
27.6%US$93.47US$24.02US$4.4114
Apr ’24US$19.88
US$53.63
+169.8%
27.8%US$92.23US$24.56US$5.2915
Mar ’24US$21.25
US$52.45
+146.8%
27.5%US$89.31US$23.97US$5.7015
Feb ’24US$21.20
US$53.34
+151.7%
26.8%US$91.77US$24.02US$5.5516
Jan ’24US$22.01
US$53.52
+143.2%
26.1%US$90.09US$24.15US$6.7416
Dec ’23US$25.81
US$52.83
+104.7%
26.6%US$90.26US$24.50US$7.0316

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 08:39
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

uniQure N.V. is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
James BirchenoughBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.